# Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

> **NCT03132454** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 32 (actual)

## Conditions studied

- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Lymphoblastic Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Dexamethasone
- **DRUG:** Palbociclib
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT03132454
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-07-25
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03132454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03132454, "Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03132454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*